Joseph Thome

Brian Abrahams

Brian Skorney

Jason Gerberry

Andrew Tsai

Paul Choi

Paul Matteis

Sarah Schram

Tessa Romero

Basma Radwan

Basma Radwan Ibrahim

Caroline Kimberly Pocher

Cory Kasimov

Danielle Brill

Dina Ramadane

Douglas Tsao

Dylan Shindler

Emily Chudy

Kyuwon Choi

Lin Tsai

Marc Goodman

Matt Marcus

Myles Minter

Nevin

- **Xenon Pharmaceuticals Inc.** announced the appointment of **Tucker Kelly** as its new **Chief Financial Officer (CFO)**, effective **October 15, 2025**.  **[1582313_0001193125-25-241546_xene-ex99_1.htm:0]** **[1582313_0001193125-25-241546_xene-20251015.htm:1]** 
- Mr. Kelly's role will be instrumental in preparing the company for the anticipated commercialization of its lead candidate, **azetukalner**, which is currently in three Phase 3 programs for the treatment of epilepsy, major depressive disorder (MDD), and bipolar depression (BPD).  **[1582313_0001193125-25-241546_xene-ex99_1.htm:0]** 
- His compensation package includes an annual base salary of **$540,000** and eligibility for an annual incentive payment of up to **45%** of his base salary.  **[1582313_0001193125-25-241546_xene-20251015.htm:1]** **[1582313_0001193125-25-241546_xene-ex10_1.htm:1]** 
- Additionally, Mr. Kelly received a one-time grant of options to purchase **225,000 common shares** at an exercise price of **$41.90 per common share**, and **30,000 restricted share units**.  **[1582313_0001193125-25-241546_xene-20251015.htm:1]** **[1582313_0001193125-25-241546_xene-ex99_1.htm:1]**

Xenon Pharmaceuticals Appoints Tucker Kelly as Chief Financial Officer

- Xenon Pharmaceuticals Inc. announced the appointment of **Tucker Kelly** as its new **Chief Financial Officer (CFO)**, effective **October 15, 2025**.  **[1582313_e037ab84f29344b78327161c786d6875_0]** **[1582313_e037ab84f29344b78327161c786d6875_1]** 
- Mr. Kelly brings over **25 years of experience** in corporate and financial strategy for life sciences companies, having most recently served as EVP, CFO, and Treasurer at Deciphera Pharmaceuticals, Inc., which was acquired for **$2.4 billion** in 2024.  **[1582313_e037ab84f29344b78327161c786d6875_1]** 
- His expertise is expected to be instrumental in preparing Xenon for the anticipated commercialization of its lead candidate, **azetukalner**, which is currently in Phase 3 programs for epilepsy, major depressive disorder, and bipolar depression.  **[1582313_e037ab84f29344b78327161c786d6875_0]** 
- In connection with his appointment, Mr. Kelly was granted an option to purchase **225,000 common shares** at an exercise price of **$41.90 per share** and **30,000 restricted share units (RSUs)**.  **[1582313_e037ab84f29344b78327161c786d6875_1]**

Xenon Pharmaceuticals Appoints Tucker Kelly as CFO

- Xenon Pharmaceuticals has initiated **two Phase I clinical trials** this year for its non-opioid pain programs, featuring the lead NAV1.7 inhibitor **XEN1701** and the lead KV7 potentiator **XEN1120**.  **[1582313_2169310_1]** **[1582313_2169310_3]** **[1582313_2169310_13]** 
- The company plans to advance these programs into **Phase II proof-of-concept studies next year**, with potential targets including acute pain models such as bunionectomy or abdominoplasty.  **[1582313_2169310_13]** **[1582313_2169310_17]** 
- Xenon Pharmaceuticals' lead NAV1.7 inhibitor, XEN1701, is designed to overcome prior limitations through **CNS penetrance, improved free fraction, and high selectivity**, aiming for a therapeutic profile that aligns with genetic data suggesting **75% to 85% NAV1.7 receptor occupancy is sufficient for complete pain loss**.  **[1582313_2169310_8]** **[1582313_2169310_10]** **[1582313_2169310_11]**

Xenon Pharmaceuticals Advances Non-Opioid Pain Programs into Phase I Clinical Trials

Xenon Pharmaceuticals (XENE)